We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Hep C Meds Patent Row Can't Stay In Minn., Fed. Circ. Says

Law360, New York (January 17, 2018, 4:17 PM EST) -- The Federal Circuit on Wednesday refused to order that a patent lawsuit brought by the University of Minnesota against Gilead Sciences Inc. over hepatitis C medications be allowed to remain in...
To view the full article, register now.




Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only


Appellate - Federal Circuit

Nature of Suit

Date Filed

November 27, 2017

Law Firms


Government Agencies


Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.